Imagnostix — a blood test to detect Alzheimer's early
Official title: Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease
Funded at 5m Biomed, LLC · NIH-11186422 · Data updated 2026-11-12
Imagnostix is a new blood test that looks for Alzheimer's-related proteins to find early brain changes in people with memory concerns or at risk for Alzheimer's.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 5m Biomed, LLC NIH-funded |
| Lab location | 1 site (Johns Creek, United States) |
| Project start | August 15, 2022 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $888,723 |
| NIH project number | 2R42AG078718-02A1 |
| Project ID | NIH-11186422 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are older adults with memory complaints, mild cognitive impairment, a family history of Alzheimer's, or other risk factors for dementia.
✕Less likely to help
People with established advanced dementia, no Alzheimer's-related pathology, or conditions that prevent blood sampling may not get direct benefit from this test.
What this research studies
If I join, I'll give blood samples so researchers can look for Alzheimer's-related proteins such as amyloid-beta 42 using a liquid biopsy platform called Imagnostix. They plan to compare blood results to established tests like PET scans and cerebrospinal fluid measures and may follow participants over time to see how markers change. The goal is to detect Alzheimer's changes before or at the earliest symptoms so people can be matched to treatments like the newly approved drugs or monitored more easily. The project is led by 5M BIOMED and will run at sites near Johns Creek, GA or partnering clinics.
Why it matters
Potential benefit: If successful, this could make diagnosing Alzheimer's earlier and easier with a simple blood test, helping people access appropriate treatments sooner.
How similar studies have gone: Other blood-based Alzheimer's biomarker studies have shown promising results and some tests are emerging clinically, but broader validation is still needed.
Where this research is happening
-
5m Biomed, LLC
Johns Creek, United States Active
Researchers
- Principal investigator: Li, Yuancheng — 5m Biomed, LLC
- Study coordinator: Li, Yuancheng
Related research
Other NIH-funded projects on the same topics.
-
Imagnostix: a simple blood-based test to flag Alzheimer’s risk
A new blood-based test called Imagnostix aims to help identify people who may be developing Alzheimer’s disease earlier and more cheaply than current methods.
-
A new method for early detection of Alzheimer's disease using blood samples
This study is working on a new, easy way to check for signs of Alzheimer's disease in blood samples, which could help doctors catch it earlier and more affordably, making it easier for more people to get tested.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.